1. Home
  2. KVUE vs DXCM Comparison

KVUE vs DXCM Comparison

Compare KVUE & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenvue Inc.

KVUE

Kenvue Inc.

N/A

Current Price

$19.30

Market Cap

36.9B

ML Signal

N/A

Logo DexCom Inc.

DXCM

DexCom Inc.

N/A

Current Price

$89.11

Market Cap

34.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KVUE
DXCM
Founded
2022
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.9B
34.4B
IPO Year
2023
2005

Fundamental Metrics

Financial Performance
Metric
KVUE
DXCM
Price
$19.30
$89.11
Analyst Decision
Buy
Strong Buy
Analyst Count
11
21
Target Price
$19.45
$85.33
AVG Volume (30 Days)
19.1M
5.5M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
4.82%
N/A
EPS Growth
40.74
47.18
EPS
0.48
1.15
Revenue
$15,124,000,000.00
N/A
Revenue This Year
$4.85
$14.46
Revenue Next Year
$2.63
$12.31
P/E Ratio
$40.27
$77.53
Revenue Growth
N/A
N/A
52 Week Low
$14.02
$54.11
52 Week High
$20.82
$92.59

Technical Indicators

Market Signals
Indicator
KVUE
DXCM
Relative Strength Index (RSI) 55.82 58.19
Support Level $18.67 $62.02
Resistance Level $20.09 N/A
Average True Range (ATR) 0.29 2.44
MACD 0.02 -0.40
Stochastic Oscillator 85.71 59.81

Price Performance

Historical Comparison
KVUE
DXCM

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

About DXCM DexCom Inc.

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.

Share on Social Networks: